Table 1.

Examples of published clinical trials of CAR T cells for the treatment of solid tumors.

Target	Cancer Subtype	Dosage	Outcome	Persistence	Ref
CD133	Carcinomas	Mean: 1.43 × 106/kg CAR T Cells	PR 1 13% (3/23) SD 2 61% (14/23)	>2 months in 7 patients.	[25]
CEA 3	Colorectal	1 × 108–1 × 1010/kg	SD 17% (1/6)	N/A	[26]
	Liver Metastases	CAR T Cells (intrahepatic)	PD 83% (5/6)
EGFR 4	NSCLC 5	Mean 0.97 × 107 cells/kg	PR 18% (2/11) SD 45% (5/11)	Up to 37 weeks	[27]
	Biliary	Mean 2.65 × 106 cells/kg	CR 6 6% (1/17) SD 59% (10/17)	One month	[28]
EGFRvIII 7	Glioblastoma	1.75–5 × 108 cells	N/A	One Month	[29]
FR-𝛼 8	Ovarian	0.3–5 × 1010 Cells	NR	3 Weeks	[24]
GD2 9	Neuroblastoma	1.2 × 107–1 × 108 cells/m2	CR 27% (3/11)	Up to 192 weeks with ATC and 96 weeks with CTLs.	[30]
GPC3 10	Hepatocellular	0.92 × 107 to 8.72 × 107 cells/kg cohort A	PR 9% (1/11)	N/A	[31]
			SD 27% (3/11)
		0.013 × 107 to 14.68 × 107 cells/kg cohort B	PD 64% (7/11)
HER2 11	Sarcoma	1 × 104–1 × 108 cells/m2	SD 24% (4/17)	9 months	[32]
	Glioblastoma	1 × 106–1 × 108 cells/m2	PR 7% (1/15)	12 weeks	[33]
			SD 27% (4/15)
	Biliary and Pancreatic Cancer	1.4–3.8 × 106 cells/kg	PR 9% (1/11) SD 45% (5/11)	80 days	[34]
IL13-R𝛼3 12	Glioblastoma	2 × 106 Cells × 1; 10 × 106 cells × 5; Intracavitary	CR 7.5 months	7 Days	[35]
Mesothelin	Mesothelioma	0.1–1 × 109 Cells × 3 1–3 × 108 cell/m2 3 times weekly for 3 weeks	1/1 PR	Up to 22 days	[36]
	Pancreatic	3 × 107–3 × 108 cell/m2	2/6 SD		[37]
	Ovarian		6/6 SD		[38]
MUC1 13	Seminal Vesicle	5 × 105 cells per metastatic site	N/A	N/A	[39]
PSMA 14	Prostate	1 × 109–1 × 1010 Cells	PR 40% (2/5)	28 Days	[40]
ROR1 15	Breast	3.3 × 105–1 × 107 cells/kg	N/A	N/A	[41]
	NSCLC
CAIX 16	RCC 17	10 daily infusions of 2 × 107–2 × 109 CAR T-cells	NR	Up to 4 weeks	[42]

¹ Partial Response. ² Stable Disease. ³ Carcinoembryonic Antigen. ⁴ Epidermal Growth Factor Receptor. ⁵ Nonsmall Cell Lung Cancer. ⁶ Complete Response. ⁷ Epidermal Growth Factor Receptor Variant III. ⁸ Folate Receptor Alpha. ⁹ Disialoganglioside GD2. ¹⁰ Glypican-3. ¹¹ Human Epidermal Growth Factor Receptor 2. ¹² Interleukin-13 Receptor Alpha-2. ¹³ Mucin-1. ¹⁴ Prostate-specific membrane antigen. ¹⁵ Receptor Tyrosine Kinase Like Orphan Receptor 1. ¹⁶ Carbonic anhydrase 9. ¹⁷ Renal Cell Carcinoma.